Clinical Trials Arena on MSN
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
"No answers. No medication. No follow-up call from my primary care physician. Just more pain, more confusion." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results